Weight-loss drugs could tackle Alzheimer's—study

A new study has found comprehensive evidence that "weight-loss" GLP-1 receptor agonists such as semaglutide are effective in tackling the biological drivers of Alzheimer's disease. The study, published in the journal Molecular and Cellular Neuroscience, examined 30 preclinical studies investigating the effects of four GLP-1 receptor agonists—liraglutide; semaglutide; exenatide; and dulaglutide—on Alzheimer's disease pathology.